Active surveillance or active treatment in localized prostate cancer?;Aktive überwachung oder aktive therapie beim lokalen prostatakarzinom?

Deutsches Arzteblatt

Volumn 106, Issue 22, 2009, Pages 371-376

  Weißbach, Lothar ^a   Altwein, Jens ^b  

^a Privatärztliche Urologische Gemeinschaftspraxis in der EuromedClinic Fürth ^*  (Germany)

^b Chirurgische Klinik Munchen Bogenhausen   (Germany)

Author keywords

Prostate cancer; Prostatectomy; PSA test; Surveillance; Treatment

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CONSERVATIVE TREATMENT; ERECTILE DYSFUNCTION; GLEASON SCORE; HUMAN; MEDICAL PRACTICE; PRACTICE GUIDELINE; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RECEIVER OPERATING CHARACTERISTIC; REVIEW; TUMOR BIOPSY; TUMOR GROWTH; URINE INCONTINENCE;

HUMANS; MALE; PALLIATIVE CARE; PREVALENCE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 70249100655     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2009.0371     Document Type: Review

References (25)

1. National Cancer Institute. SEER-Studie: www.seer.cancer.gov/statfacts/ html/prost.html?statfacts-page=prost.html&x=18&y=16)
2. Lu-Yao G, Lao S: Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997; 349: 906-910 (Pubitemid 27139819)
3. Catalona WJ: Expectant management and the natural history of local-ized prostate cancer. J Urol 1994; 152: 1751-1752 (Pubitemid 24322621)
4. DRG-Statistik 2006: InEK: Datenveröffentlichung gemäß § 21 KHEntgG: www.g-drg.de/cms/index.php/inek-site-de/content/view/full/ 1629
5. Tumorzentrum Brandenburg: www.tumorzentrum-brandenburg.de/pwp/ (S(temi1ujch4e0rmza1bo4wfyl))/uploads/Sachbericht-2007.pdf
6. Walsh PC, DeWeese TL, Eisenberger MA: Clinical practice. Localized prostate cancer. N Engl J Med. 2007; 357: 2696-2705
7. Zelefsky MU, Chan H, Hunt M: Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006; 176: 1415-1419 (Pubitemid 44307191)
8. Parker C: Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 2004; 5: 101-106 (Pubitemid 38145893)
9. Allaf ME, Carter HB:The results of watchful waiting for prostate cancer. AUA update Series 2005; 24: 2-7.
10. Studer UE, Collette L, Whelan P et al.: Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008; 53: 941-949
11. Mohler JL, Williams BT, Freeman JA: Expectant management as an option for men with stage T1c prostate cancer: a preliminary study. World J Urol 1997; 15: 364-368
12. Choo R, Klotz L, Danjoux C et al.: Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002; 167: 1664-1669 (Pubitemid 34240696)
13. Chen WM, Yang CR, Ou YC et al.: Clinical outcome of patients with stage T1a prostate cancer. J Chin Med Assoc 2003; 66: 236-240 (Pubitemid 37265534)
14. Khan MA, Carter HB, Epstein JI et al.: Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant managemant criteria for prostate cancer? J Urol 2003; 170: 2274-2278
15. Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT: An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 2004; 171: 1520-1524 (Pubitemid 38365409)
16. Martin RM, Gunnell D, Hamdy F, Neal D, Lane A, Donovan J: Continuing contro-versy over monitoring men with localized prostate cancer: a systematic review on programs in the prostate specific antigen era. J Urol 2006; 176: 439-449 (Pubitemid 43927893)
17. Klotz L: Active Surveillance for prostate cancer: for whom? J Clin Oncol 2005; 23: 8165-8169
18. American Urological Association: Guideline prostate cancer. www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm
19. National Institute for Health and Clinical Excellence: Prostate cancer. www.nice.org.uk/guidance/index.jsp?action=byID&o=11924
20. D'Amico AV, Whittington R, Malkowicz SB et al.: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974 (Pubitemid 28445094)
21. Epstein JI, Chan DW, Sokoll LJ et al.: Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998; 160: 2407-2411
22. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR: Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 2007; 178: S14-19
23. Kattan MW, Eastham JA, Wheeler TM et al.: Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated,confined tumors. J Urol 2003; 170: 1792-1797
24. Cooperberg MR, Broering JM, Litwin MS et al.: The contemporary management of prostate cancer in the United States: Lessons from the Cancer of the Prostate Urologic Strategic Research Endeavour (CaPSURE), a National Disease Registry. J Urol 2004; 171: 1393-1401
25. Warlick C, Trock BJ, Landis P, Epstein JI, Carter HB: Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 2006; 98: 355-357 (Pubitemid 43338215)